Table 4.
Secondary outcome measures
| Group | PUFA | Placebo | ||
|---|---|---|---|---|
| Characteristic | Baseline | 48 w | Baseline | 48 w |
| Aspartate amino transferase (IU/dl) | 47.7±22.8 | 41.7±17.4 | 47.8±22.1 | 47.9±38.1 |
| Alanine amino transferase (IU/dl) |
60.1±27.6 | 56.9±30.9 | 66.7±44.9 | 59.6±43.8 |
| Serum bilirubin (mg/dl.) | 1.1±0.3 | 1.1±0.3 | 1.0±0.1 | 1.0±0.0 |
| Blood glucose (mg/dl) | 129.9±36.5 | 150.4±43.7a | 121.5±38.4 | 123.5±22.9 |
| Insulin (mIU/L) | 37.7±17.7 | 42.3±20.7 | 55.4±50.6 | 43.6±21.6 |
| HOMA | 12.0±6.8 | 16.1±10.3a | 15.8±15.2 | 13.1±7.3 |
| HbA1C (g/dl) | 6.7±0.9 | 7.5±2.2b | 6.7±0.7 | 6.9±1.1 |
| Serum triglycerides (mg/dl) | 175.2±91.6 | 211.5±160.8 | 232.1±174.5 | 177.4±66.0 |
| Serum HDL (mg/dl.) | 40.6±7.1 | 43.2±8.9 | 40.8±9.4 | 41.6±9.3 |
| Total cholesterol | 177.9±40.2 | 182.5±55.5 | 189.6±47.4 | 187.2±32.1 |
All values mean±SD
a
p<0.05 compared to baseline;
b
p= 0.059 compared to baseline